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Abstract
Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-
acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher
risk of developing cirrhosis and hepatocellular carcinoma and lower sustained virological response (SVR) rates. Currently there
are 4 recommended drugs for the treatment of HCV genotype 3: pegylated interferon (PegIFN), sofosbuvir (SOF), daclatasvir
(DCV) and ribavirin (RBV). Treatment with PegIFN, SOF and RBV for 12 weeks has an overall SVR rate of 83–100%, without
significant differences among cirrhotic and non-cirrhotic patients. However, this therapeutic regimen has several contra-
indications and can cause significant adverse events, which can reduce adherence and impair SVR rates. SOF plus RBV for
24 weeks is another treatment option, with SVR rates of 82–96% among patients without cirrhosis and 62–92% among those
with cirrhosis. Finally, SOF plus DCV provides 94–97% SVR rates in non-cirrhotic patients, but 59–69% in those with cirrhosis.
The addition of RBV to the regimen of SOF plus DCV increases the SVR rates in cirrhotic patients above 80%, and extending
treatment to 24 weeks raises SVR to 90%. The ideal duration of therapy is still under investigation. For cirrhotic patients, the
optimal duration, or even the best regimen, is still uncertain. Further studies are necessary to clarify the best regimen to treat
HCV genotype 3 infection.
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Introduction
The hepatitis C virus (HCV) comprises six genotypes and
multiple subtypes (1). HCV genotype 1 is the most prevalent
worldwide, accounting for 83.4 million infections (46.2% of
all HCV patients) and is the most prevalent in the Americas,
Europe and Australia (2). Genotype 3 is the second most
prevalent globally (54.3 million patients, 30.1%); geno-
types 2, 4, and 6 are responsible for 22.8% and genotype 5
comprises the remaining less than 1% of patients (2).
Evidence that HCV genotype 3 increases the risk of
progression to cirrhosis or to hepatocellular carcinoma (HCC)
was published in the last years. The Swiss Hepatitis C
Cohort Study found that the most significant independent
risk factors associated with accelerated liver fibrosis pro-
gression, in a multivariate model analysis, were histologi-
cal activity [OR=2.03 (1.54–2.68), Po0.001], genotype 3
infection [OR=1.89 (1.37–2.61), Po0.001], male sex
[OR=1.60 (95%CI=1.21–2.12), Po0.001] and age at
infection [OR=1.08 (1.06–1.09), Po0.001] (3). Among
patients with HCV infection and cirrhosis, genotype 3
infection is also the strongest predictor for the occurrence
of HCC. In a French cohort, the rate of HCC occurrence
after 5 years was 34% among those with cirrhosis due to
chronic HCV genotype 3, and 17% in other genotypes
(P=0.013) (4).
Until 2011, the only treatment options available for patients
with HCV infection were interferon-based regimens, with
pegylated interferon alfa 2a or 2b (PegIFN) and ribavirin
(RBV). In 2011 the first direct-acting antiviral agents (DAAs),
NS3/4A protease inhibitors (telaprevir and boceprevir)
became available for HCV genotype 1 infection and their
association with PegIFN/RBV improved the sustained viro-
logical response (SVR) rates (5,6). However, NS3/4A protease
inhibitors have limited activity against HCV genotype 3,
even considering second-generation drugs such as sime-
previr and paritaprevir.
In 2013, new DAAs became available for HCV infection
treatment, though few are effective for HCV genotype 3
infection, such as daclatasvir (DCV) and sofosbuvir (SOF).
SOF is a pyrimidine nucleotide analogue inhibitor of the
HCV RNA-dependent RNA polymerase, with excellent anti-
viral activity against all HCV genotypes and a high genetic
barrier to resistance (7). DCV is a HCV NS5A inhibitor that
reduces the assembly of the replication complex and also
has antiviral activity across all genotypes (8). NS5A is a
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zinc-binding phosphoprotein that plays an important,
although not totally clear, role in HCV replication.
Currently, only four drugs (PegIFN, RBV, SOF and
DCV) are recommended by the European Association for
the Study of the Liver (EASL) and the American Associa-
tion for the Study of Liver Diseases (AASLD) for the treatment
of HCV genotype 3 infection (9,10). As a consequence, a
small number of effective treatment options are available
for patients infected by HCV genotype 3. The EASL guide-
lines recommend six treatment options for patients infected
with HCV genotype 1, and only three for genotype 3 (9).
Similarly, AASLD recommends four treatment options for
patients infected with HCV genotype 1, while for genotype
3 there are only two therapeutic regimens recommended
and one alternative option (10).
In addition, the first interferon-free regimen available
for genotype 3 treatment, SOF plus RBV for 24 weeks,
showed a remarkably low SVR rate of 62% for cirrhotic
patients who have not responded previously to PegIFN/
RBV therapy (11).
At the moment, patients with HCV genotype 3 infections
are considered a special population and have become one
of the most challenging subpopulations to treat. Studies
have shown that genotype 3 is associated with faster
progression to cirrhosis and, thus, has a higher likelihood
of hepatocellular carcinoma in comparison to the other
genotypes (3,4). In addition, few effective treatment options
are available and the use of some therapeutic options is
not yet supported by clinical trial data in this subset of
patients. Finally, patients with HCV genotype 3 infection and
cirrhosis, especially those who are treatment-experienced,
have the lowest SVRs in the DAA era.
Given this context, this article reviews the combina-
tions of drugs that can be used for the treatment of HCV
genotype 3 infection with and without cirrhosis.
Material and Methods
A PubMed search was undertaken to identify relevant
literature using search terms including "hepatitis C treatment",
"HCV treatment", "HCV genotype 3", "HCV genotype 3
therapy", "sofosbuvir" and "daclatasvir". Furthermore,
abstracts presented at recent international meetings in
liver disease, viral hepatitis and infectious disease, as well
as the reference lists of the AASLD and EASL guidelines
were searched to identify publications not retrieved by
PubMed searches.
Treatment of HCV genotype 3 infection in
non-cirrhotic patients: sofosbuvir plus ribavirin
The combination of SOF plus RBV for 24 weeks was
the first interferon-free therapy for patients with HCV
genotype 3 infection approved by the FDA. International
guidelines differ regarding the recommendations for this
regimen. EASL guidelines do not recommend this therapeutic
regimen for treatment-experienced cirrhotic patients. On
the other hand, AASLD recommends SOF plus RBV as
an alternative regimen for patients without cirrhosis with
previous PegIFN/RBV failure or treatment-naive patients
who are IFN-ineligible (9,10).
In naive non-cirrhotic patients with HCV genotype 3
infection, SOF plus RBV for 12 weeks resulted in an
overall SVR of 61–68%. However, extending the treatment
to 24 weeks led to an approximate 30% increase in SVR
rates, ranging from 90 to 96% (Table 1).
Two large clinical trials evaluated the efficacy of SOF
plus RBV for 12 weeks in naive, non-cirrhotic patients
infected with HCV genotype 3. The Fission trial included
145 patients, but only 89 (61%) achieved SVR (12).
The Positron trial included 84 naive patients who were
interferon-ineligible or intolerant, of which 57 (68%) reached
SVR (13). The Boson clinical trial found higher SVR
among naive and non-cirrhotic patients treated with
SOF plus RBV for 16 weeks. Among 70 patients treated,
58 (83%) achieved SVR (14). Another arm of this study
evaluated 72 naive non-cirrhotic patients treated for
24 weeks, with an overall SVR of 90% (65 patients).
SOF plus RBV for 24 weeks was also used in the Valence
trial, which included 92 patients and 87 (96%) achieved
SVR (11).
In treatment-experienced, non-cirrhotic patients with
HCV genotype 3, SOF plus RBV for 12 weeks resulted in
low SVR rates (37%), similar to what was observed in the
naive population. Extending treatment to 24 weeks led
to an approximate 50% increase in SVR rates, ranging
from 82 to 96% (Table 1). The Fusion trial investigated
12 or 16 weeks of SOF plus RBV in previous treatment-
experienced non-cirrhotic patients with HCV genotype 3
infection (13). Thirty eight patients were treated for 12 weeks
and 40 patients for 16 weeks and the SVR rates were,
respectively, 38% (14 of 38) and 63% (25 of 40). The Boson
study also evaluated SOF plus RBV for 16 weeks in 54 non-
cirrhotic patients and previous non-responders to PegIFN/
RBV, with 41 (76%) achieving SVR (14).
Finally, two studies evaluated SOF plus RBV for
24 weeks in non-cirrhotic patients and previous non-
responders to PegIFN/RBV. The Boson study included
54 patients, 44 (82%) of whom achieved SVR (14). The
Valence study included 92 patients and 87 (96%) achieved
SVR (11).
In conclusion, combination therapy of SOF plus RBV
for 24 weeks has been shown to yield a high SVR rate in
naive patients or previous PegIFN/RBV non-responders
with HCV genotype 3 without cirrhosis. Shorter therapies
have not been able to reach acceptable SVR rates.
Sofosbuvir plus pegylated interferon/
ribavirin
The combination of SOF plus PegIFN/RBV for 12 weeks
is the only interferon based therapy recommended by the
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EASL and AASLD guidelines for the treatment of HCV
genotype 3 infection (9,10).
In naive non-cirrhotic patients, SOF plus PegIFN/RBV
for 12 weeks resulted in an overall SVR of 92–100%
(Table 1). However, efficacy data is scarce: few patients
were included in clinical trials and only three studies (two
phase II studies and one phase III study) evaluated the
SVR rates in this population. The phase II study included
25 naive non-cirrhotic patients (15 with HCV genotype 2
and 10 with genotype 3 infection) treated with SOF plus
PegIFN/RBV for 12 weeks, reaching an overall SVR rate
of 92%, but no SVR data according to specific genotype is
available (15). Another phase II study included 17 patients
treated with SOF plus PegIFN/RBV for either 12 (7 patients)
or 8 weeks (10 patients) and the overall SVR rate was
100% in both arms (16). The Boson phase III study
included 71 naive non-cirrhotic patients with HCV geno-
type 3 infection treated with SOF plus PegIFN/RBV for
12 weeks, achieving an overall SVR rate of 96% (14).
In treatment-experienced non-cirrhotic patients, SOF
plus PegIFN/RBV for 12 weeks resulted in overall SVR
rates of 83–94% (Table 1), although these results are
supported by data from only two studies with 64 patients.
Lonestar, a phase II study, included only 12 patients
without cirrhosis, of which 10 (83%) achieved SVR, one
relapsed and the other was lost to follow-up (17). Boson,
a phase III study, included 52 non-cirrhotic patients with
genotype 3 HCV infection and previous failure to PegIFN/
RBV, with an overall SVR rate of 94% (14).
In non-cirrhotic patients, including naive and with pre-
vious failure to PegIFN/RBV, SOF plus PegIFN/RBV for
12 weeks resulted in high SVR rates (83–100%) (Table 1).
It must be noted that non-significant differences in
SVR rates were observed among naive and treatment-
experienced patients, but these data need to be cautiously
analyzed, since only small cohorts were included in the
studies.
Sofosbuvir plus daclatasvir with or without
RBV
The combination SOF plus DCV for 12 weeks is recom-
mended by EASL and AASLD for the treatment of patients
with HCV genotype 3 infection (9,10). In non-cirrhotic
patients with HCV genotype 3 infection, whether naive
or treatment-experienced, SOF plus DCV with or without
RBV for 12 or 24 weeks resulted in an overall SVR of
80–100% (Table 2).
Among naive or treatment-experienced patients with-
out cirrhosis, treatment with SOF plus DCV for 12 weeks
resulted in an overall SVR of 94–97% (Table 2). Two
studies evaluated SOF plus DCV for 12 weeks in naive or
treatment-experienced non-cirrhotic patients with HCV
genotype 3 infection (18,19). ALLY-3, a phase III clinical
trial, included 75 naive and 34 previously treatment-
experienced patients and SVR rates were, respectively,
97% (73 of 75) and 94% (22 of 34) (Table 2) (19). An
observational study included 25 naive and treatment-
experienced patients, 24 of whom (96%) achieved SVR
(Table 2) (19).
A single study, ALLY-3+, evaluated the addition of
RBV to SOF plus DCV for 12 or 16 weeks for HCV
Table 1. Summary of sustained virological response (SVR) rates in non-cirrhotic patients with hepatitis C
virus (HCV) genotype 3 infection treated with sofosbuvir (SOF) plus pegylated interferon (PegIFN)/ribavirin
(RBV) or SOF plus RBV.
Treatment (reference number) Weeks n Previous treatment SVR (%)
SOF plus PegIFN/RBV (15) 12 10 naive 92*
SOF plus PegIFN/RBV (14) 12 71 naive 96
SOF plus PegIFN/RBV (16) 8 10 naive 100
SOF plus PegIFN/RBV (16) 12 7 naive 100
SOF plus PegIFN/RBV (17) 12 12 experienced 83
SOF plus PegIFN/RBV (14) 12 52 experienced 94
SOF plus RBV (12) 12 145 naive 61
SOF plus RBV (13) 12 84 naive 68
SOF plus RBV (14) 16 70 naive 83
SOF plus RBV (14) 24 72 naive 90
SOF plus RBV (11) 24 92 naive 96
SOF plus RBV (13) 12 38 experienced 37
SOF plus RBV (13) 16 40 experienced 63
SOF plus RBV (14) 16 54 experienced 76
SOF plus RBV (14) 24 54 experienced 82
SOF plus RBV (11) 24 92 experienced 96
* This SVR rate included 15 naive non-cirrhotic patients with HCV genotype 2 infection.
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genotype 3 naive or treatment-experienced patients without
cirrhosis, including 14 patients with advanced fibrosis, but
without cirrhosis. Six patients were treated for 12 weeks
and 8 patients were treated for 16 weeks with SOF plus
DCV and RBV, with all of them achieving SVR12 in both
the 12- and 16-week treatment arms (20).
Another study evaluated SOF plus DCV with or without
RBV for 12 or 24 weeks in naive or treatment-experienced
patients with HCV genotype 3 (21). The SVR rates were,
respectively, 92% (11 of 12) with 12 weeks of treatment
and 83% (5 of 6) with longer treatment for 24 weeks (21).
Therefore, the addition of RBV did not seem to improve
the outcome of therapy, since high SVR rates were
observed in patients treated with SOF plus DCV with or
without RBV, but both treatment arms included only a
small number of patients.
Finally, one observational study assessed the SVR
rates in patients treated for 24 weeks with SOF plus DCV
with or without RBV (19). Among the 29 patients treated
with SOF plus DCV without RBV, 29 (100%) achieved
SVR, while among 5 patients treated with SOF plus
DCV with the addition of RBV for 24 weeks, 4 (80%)
achieved SVR.
To summarize, the addition of RBV for non-cirrhotic
genotype 3 patients treated with SOF plus DCV did not
alter SVR rates significantly. Increasing the duration of
treatment from 12 to 24 weeks also did not result in higher
SVR rates. It is important to emphasize that the SVR
rates discussed above are based on few clinical trials and
observational studies that included small populations.
Treatment of HCV genotype 3 with
compensated cirrhosis: sofosbuvir plus
ribavirin
SOF plus RBV for 12 weeks is not recommended for
treatment of cirrhotic patients with HCV genotype 3 infec-
tions. The overall SVR rates in naive cirrhotic patients
treated for 12 weeks ranged from 21 to 34% (Table 3).
Two trials found that SOF plus RBV for 12 weeks for
naive patients with cirrhosis resulted in SVR rates of 21%
(3 of 14) and 34% (13 of 38) (12,13).
Extending the treatment with SOF plus RBV in this
population improved the SVR rates (Table 3). The Boson
study included 21 naive patients with cirrhosis treated with
SOF plus RBV for 16 weeks and 12 (57%) achieved SVR (14).
Extending the treatment for 24 weeks in this population
improved the SVR rates from 82 to 92% (Table 3). In the
Boson study, among 22 naive patients with cirrhosis
treated with SOF plus RBV for 24 weeks, 18 (82%)
achieved SVR (14). In the Valence study, 12 of 13 patients
(92%) achieved SVR (11). SOF plus RBV for 24 weeks is
recommended by EASL for treatment-naive patients with
cirrhosis and by AASLD as an alternative regimen for
treatment-naive patients with HCV genotype 3 infection
who are IFN-ineligible (9,10).
Among treatment-experienced patients with cirrhosis
and HCV genotype 3 infection treated with SOF plus RBV
for 12 weeks, the SVR rates are around 20%, similar
to those observed in naive patients (Table 3). Only one
study, the Fusion trial, assessed SOF plus RBV for 12 weeks
in treatment-experienced patients with cirrhosis, including
26 patients, and only 20% achieved SVR (13).
In this population, as observed in naive patients,
extending the treatment duration with SOF plus RBV
improved the SVR rates. Two studies evaluated SOF plus
RBV for 16 weeks in treatment-experienced patients. The
Boson study included 36 patients, reaching 47% SVR
(17 patients) (14). The Fusion study included 23 patients,
of which 14 (61%) achieved SVR (13). Finally, two other
studies evaluated the extension of the treatment regimen
with SOF plus RBV from 12 to 24 weeks in this population.
In the first study only 60% (29 of 47) of prior treatment-
experienced patients achieved SVR (11). The other study,
Boson, comprising 34 patients, had a 77% SVR rate
(20 patients) (14). SOF plus RBV for 24 weeks in treatment-
experienced patients with cirrhosis resulted in low SVR
rates, below 80%. Therefore, the EASL and the AASLD
Table 2. Summary of sustained virological response (SVR) rates in non-cirrhotic patients with hepatitis C
virus (HCV) genotype 3 infection treated with sofosbuvir (SOF) plus daclatasvir (DCV) with or without
ribavirin (RBV).
Treatment (reference number) Weeks n Previous treatment SVR (%)
SOF plus DCV (18) 12 75 naive 97
SOF plus DCV (18) 12 34 experienced 94
SOF plus DCV (19) 12 25 naive/experienced 96
SOF plus DCV with RBV (20) 12 6 naive/experienced 100
SOF plus DCV with RBV (20) 16 8 naive/experienced 100
SOF plus DCV ± RBV (23) 12 12 naive/experienced 92
SOF plus DCV ± RBV (23) 24 6 naive/experienced 83
SOF plus DCV (19) 24 29 naive/experienced 100
SOF plus DCV with RBV (19) 24 5 naive/experienced 80
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guidelines do not recommend this therapeutic regimen for
treatment-experienced cirrhotic patients with HCV geno-
type 3 infection (9,10).
Sofosbuvir plus and ribavirin
The combination SOF plus PegIFN/RBV for 12 weeks
is recommended by EASL and AASLD for the treatment
of naive or treatment-experienced patients with com-
pensated cirrhosis and HCV genotype 3 infection (9,10).
This recommendation is based in only one study, which
observed an overall SVR rate of 86–92% in compensated
cirrhotic patients (Table 3).
The Boson phase III study found SVR rates of 91% for
the treatment of 23 naive patients with compensated
cirrhosis with SOF plus PegIFN/RBV for 12 weeks (14).
The treatment-experienced cirrhotic population was evaluated
in two studies, which assessed the SVR rates with SOF plus
PegIFN/RBV for 12 weeks (14,17). The Boson study included
35 patients and 30 (86%) achieved SVR (14). Lonestar, a
phase II study, included 12 treatment-experienced cirrhotic
patients and ten (92%) reached SVR (17).
Even though it was only evaluated in small cohorts, the
regimen containing SOF plus PegIFN/RBV for 12 weeks
presents an adequate option for patients with compen-
sated cirrhosis; however, interferon-based therapy may
have some contraindications and is also associated with
high rates of adverse events, especially in the cirrhotic
population, justifying the ongoing search of safer and
more effective therapies for these patients.
Sofosbuvir plus daclatasvir with or without
RBV
The combination of SOF plus DCV for 24 weeks is
recommended by the EASL and the AASLD guidelines for
the treatment of cirrhotic patients with HCV genotype 3
infection (9,10). In naive or treatment-experienced patients
with cirrhosis, 12 weeks of SOF plus DCV or SOF plus
DCV and RBV resulted in overall SVR rates of 58–69%
and 80–83%, respectively (Table 4). Furthermore, the
extension of the treatment to 24 weeks with SOF plus
DCV or SOF plus DCV and RBV resulted in increased
overall SVR rates of 90–100% and 85%, respectively
(Table 4).
Two studies assessed the SVR rates in naive or treatment-
experienced cirrhotic patients treated with SOF plus DCV
for 12 weeks. ALLY-3 included 19 naive and 13 treatment-
experienced patients with cirrhosis treated with SOF plus
DCV for 12 weeks, with SVR rates of, respectively, 58%
(11 of 19) and 69% (9 of 13) (18). An observational study
included 30 patients with compensated cirrhosis, naive or
previously treatment-experienced (77% had previously
been treated with PegIFN plus RBV), who were treated
with SOF plus DCV (only 4 patients received RBV) for
12 weeks and 24 (80%) achieved SVR (19).
ALLY-3+ evaluated SVR rates with SOF plus DCV
and RBV for 12 weeks and the extension of the treatment
to 16 weeks in naive or experienced patients. This study
included 18 patients treated with SOF plus DCV with RBV
for 12 weeks and 18 patients treated for 16 weeks, observ-
ing SVR rates of, respectively, 83% (15 of 18) and 89%
(16 of 18) (20).
Two observational studies evaluated SVR rates among
naive or experienced patients with cirrhosis treated with
SOF plus DCV for 24 weeks (19,22). One study included
100 patients and 90 (90%) achieved SVR (19). Another
study included only 19 patients and all achieved SVR (22).
Other observational studies evaluated SOF plus DCV with
the addition of RBV for 24 weeks. In one study, 33 patients
were included and 28 (85%) achieved SVR while in the
other study, among 13 patients treated with SOF/DCV for
Table 3. Summary of sustained virological response (SVR) rates in cirrhotic patients with hepatitis C virus
(HCV) genotype 3 infection treated with sofosbuvir (SOF) plus pegylated interferon(PegIFN)/ribavirin(RBV)
or SOF plus RBV.
Treatment (reference number) Weeks n Previous treatment SVR (%)
SOF plus PegIFN/RBV (14) 12 23 naive 91
SOF plus PegIFN/RBV (14) 12 35 experienced 86
SOF plus PegIFN/RBV (17) 12 12 experienced 83
SOF plus RBV (13) 12 14 naive 21
SOF plus RBV (15) 12 38 naive 34
SOF plus RBV (14) 16 21 naive 57
SOF plus RBV (14) 24 22 naive 82
SOF plus RBV (11) 24 12 naive 92
SOF plus RBV (13) 12 26 experienced 20
SOF plus RBV (14) 16 36 experienced 47
SOF plus RBV (13) 16 23 experienced 61
SOF plus RBV (11) 24 47 experienced 62
SOF plus RBV (14) 24 34 experienced 77
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24 weeks with the addition of RBV, 11 (85%) achieved
SVR (19,23).
In conclusion, SOF plus DCV without RBV for 12 weeks
had unacceptably low SVR rates, overall below 70% in
cirrhotic patients with HCV genotype 3 infection. However,
the addition of RBV improves SVR rates up to 80%. Further-
more, in this population the highest SVR rates, ranging
from 85 to 100%, were observed with SOF plus DCV with
RBV for 24 weeks, although stronger recommendations
are not possible, since most studies were observational
and included only a small number of patients.
Treatment of HCV genotype 3 infection with
decompensated cirrhosis with sofosbuvir
and daclatasvir
Patients with HCV genotype 3 infection and decom-
pensated cirrhosis have only one treatment recommenda-
tion according to the AASLD and EASL guidelines: SOF
plus DCV for 12 or 24 weeks, with or without RBV. EASL
recommended that patients with decompensated cirrhosis
(Child-Pugh B and C) not listed for liver transplantation
should be treated with the combination of SOF plus DCV
and RBV for 12 weeks and for those patients presenting
with contraindications to the use of RBV, EALS recom-
mends extending SOF plus DCV treatment for 24 weeks (9).
AASLD recommends SOF plus DCV with RBV for 12 weeks
in patients with HCV genotype 3 infections who have
decompensated cirrhosis, regardless of their status as
candidates for liver transplantation, including those with
hepatocellular carcinoma (10).
Four studies evaluated SOF plus DCV in patients with
decompensated cirrhosis and HCV genotype 3 infection
(19,23–25). The ALLY-1 study evaluated patients with
compensated and decompensated cirrhosis or post-liver
transplant recurrence treated for 12 weeks with SOF plus
DCV and RBV. Among six patients with compensated/
decompensated cirrhosis, five (83%) achieved SVR,
which was slightly better in transplant recipients, 10 of
11 (91%) (24).
In an observational study, among 114 patients with
decompensated cirrhosis treated with SOF plus DCV with
RBV for 12 weeks, 70% achieved SVR. Seven patients
treated with SOF plus DCV without RBV had a similar
SVR rate, of 71% (25). In another observational study,
cirrhotic patients with Child-Pugh B or C were divided in
three treatment arms: SOF plus DCV for 12 weeks, SOF
plus DCV for 24 weeks or SOF plus DCV with RBV for
24 weeks. The observed SVR rates were, respectively,
33% (2 of 6), 71% (12 of 17) and 70% (7 of 10) (19).
Finally, another observational study evaluated the SVR
rates in patients with compensated or decompensated cir-
rhosis with HCV genotype 3 infection treated for 24 weeks
with SOF plus DCV with or without RBV (22). Among those
treated with SOF plus DCV, SVR rates were 100% for
Child-Pugh A (19 of 19), 80% for Child-Pugh B (12 of 15),
and 75% for Child-Pugh C (6 of 8). Conversely, among
those who added RBV, response rates were 85% (11 of
13) for Child-Pugh A, 86% (12 of 14) for Child-Pugh B, and
100% (2 of 2) for Child-Pugh C (22).
Conclusions
How can we best interpret the treatment responses for
HCV genotype 3 treatments? To choose the best avail-
able therapeutic regimen is not simple, since some patient-
related factors can negatively influence treatment outcomes,
such as the presence of cirrhosis and previous treatment
history for HCV.
The overall SVR rate obtained with SOF plus PegIFN/
RBV for 12 weeks was high and no significant differences
among cirrhotic and non-cirrhotic patients were observed
(Figure 1). However, this therapeutic regimen includes
PegIFN, a drug that requires subcutaneous injections,
which can reduce adherence to treatment. Furthermore,
the combination of PegIFN/RBV can cause several adverse
Table 4. Summary of sustained virological response (SVR) rates in cirrhotic patients with hepatitis C virus
(HCV) genotype 3 infection treated with sofosbuvir (SOF) plus daclatasvir (DCV) with or without ribavirin
(RBV).
Treatment (reference number) Weeks n Previous treatment SVR (%)
SOF plus DCV (18) 12 19 naive 58
SOF plus DCV (18) 12 13 experienced 69
SOF plus DCV (19) 12 33 naive/experienced 70
SOF plus DCV with RBV (20) 12 18 naive/experienced 83
SOF plus DCV with RBV (20) 16 18 naive/experienced 89
SOF plus DCV (19) 24 29 naive/experienced 100
SOF plus DCV (23) 24 19 naive/experienced 100
SOF plus DCV with RBV (19) 24 33 naive/experienced 85
SOF plus DCV with RBV (23) 24 13 naive/experienced 85
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effects that can lead to early treatment discontinuation,
especially in cirrhotic patients, and it is contraindicated for
a substantial number of patients (since previous studies
have determined that approximately 17% of HCV-infected
patients in the general US population had at least one
contraindication to its use) (26,27).
The combination of SOF plus RBV for 24 weeks showed
high SVR rates among naive patients with or without cirrho-
sis, but remains disappointing in treatment-experienced
patients with cirrhosis. In addition, this therapeutic option
has inconveniently longer treatment duration (24 weeks),
which can increase costs and reduce patient adherence.
SOF plus DCV for 12 weeks provides very high SVR
rates in non-cirrhotic patients (94–97%), but in those
with cirrhosis the overall SVR of 59–69% is less than
satisfactory. The addition of RBV increases the SVR rates
in cirrhotic patients to above 80% and extending treat-
ment to 24 weeks raises SVR rates to 90%. Nevertheless,
it remains unclear if 12 weeks is enough for all patients or
24 weeks is the best option for some special populations,
such as cirrhotic patients. For cirrhotic patients, the optimal
duration, or even the best regimen, remains uncertain. Fur-
ther studies are needed to clarify the best therapeutic
regimen for patients with HCV genotype 3 infection.
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